Dmitry Balyasny’s Praxis Precision Medicines PRAX Stock Holding History

Dmitry Balyasny’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$629K	Buy	+1,880	New	+$595K	﹤0.01%	2426
2025 Q3	–	Sell	-369,254	Closed	-$15.5M	–	3363
2025 Q2	$15.5M	Sell	369,254 -33,749	-8%	-$1.29M	0.02%	771
2025 Q1	$15.3M	Buy	+403,003	New	+$25.2M	0.03%	710
2024 Q2	–	Sell	-13,311	Closed	-$812K	–	2990
2024 Q1	$812K	Buy	+13,311	New	+$597K	﹤0.01%	1876
2023 Q3	–	Sell	-688	Closed	-$11.9K	–	2627
2023 Q2	$11.9K	Buy	+688	New	+$10.5K	﹤0.01%	2172
2022 Q4	–	Sell	-1,671	Closed	-$57K	–	3140
2022 Q3	$57K	Buy	+1,671	New	+$83.3K	﹤0.01%	2462

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Dmitry Balyasny's PRAX Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 1,880 shares worth $629K. The stake represents ﹤0.01% of the portfolio and ranks #2426 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in PRAX as recently as Q2 2025.

Dmitry Balyasny first reported a position in PRAX in Q3 2022 and has held it in 6 quarters since. The position peaked at $15.5M in Q2 2025. 307 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Dmitry Balyasny held 1,880 shares of Praxis Precision Medicines worth $629K as of Q2 2026.
Praxis Precision Medicines was a new Dmitry Balyasny position in Q2 2026.
Praxis Precision Medicines made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2426 holding.
Dmitry Balyasny first reported a position in Praxis Precision Medicines in Q3 2022 and has held it in 6 quarters since.
Dmitry Balyasny's Praxis Precision Medicines position peaked at $15.5M in Q2 2025.
307 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.